

Diaceutics PLC
("Diaceutics" or the "Group")

Growth & Innovation Forum 2020

Diaceutics PLC (AIM: DXRX), the diagnostic commercialisation company, announces it will be exhibiting at the Growth & Innovation Forum 2020 on Tuesday 11 February at the Business Design Centre, London.

Members of the Diaceutics management team will be at stand 23 throughout the day and Peter Keeling, CEO, will be presenting at 11.45am in the Babbage Room.

This is a one-day investor event where the exhibiting companies are focused on growth and technology. The show attracts both institutional and retail investors. For further information, please visit the event website at: <https://www.sharesmagazine.co.uk/events/event/growth-innovation-forum-2020-1>

Enquiries:

Diaceutics PLC
Peter Keeling, Chief Executive Officer
Philip White, Chief Financial Officer

www.diaceutics.com
Via Walbrook PR

Walbrook PR
Anna Dunphy
Paul McManus

Tel: +44 (0)20 7933 8780 or diaceutics@walbrookpr.com
Mob: +44 (0)7876 741 001
Mob: +44 (0)7980 541 893

About Diaceutics

Diaceutics PLC is a leading diagnostics data analytics and implementation services provider for global pharmaceutical companies. The Company, quoted on the Alternative Investment Market (AIM) of the London Stock Exchange, is enabling Pharma to accelerate their market penetration and achieve a better return on precision medicine therapies by helping them to revolutionise patient testing. By generating insights from its data lake of clinical laboratory testing data and other data, Diaceutics helps Pharma understand and leverage the diagnostic landscape through initiatives that improve patient testing, leading to better treatment outcomes. The Company works with more than 30 global pharmaceutical companies across hundreds of precision medicine projects. The Company employs a leading global group of experts from the laboratory, diagnostic and pharmaceutical industries. www.diaceutics.com

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

END

NRAFLFFRFLIEIII